Welcome to our dedicated page for AI / ML Innovations news (Ticker: AIMLF), a resource for investors and traders seeking the latest updates and insights on AI / ML Innovations stock.
AI/ML Innovations Inc. (AIMLF) delivers cutting-edge artificial intelligence and machine learning solutions for digital health transformation. This page provides investors and industry professionals with essential updates about the company's strategic initiatives, regulatory milestones, and technological advancements.
Access comprehensive coverage of AIMLF's partnerships with Health Gauge Inc., AI Rx Inc., and other key players in healthcare technology. Track developments stemming from acquisitions like Quantum Sciences Ltd. and stay informed about operational updates across neural networks, cloud computing integrations, and precision healthcare platforms.
Key updates include: earnings reports, strategic investment announcements, regulatory filings, and leadership changes. Our curated news collection ensures you receive accurate information about the company's progress in developing AI-powered diagnostic tools and patient engagement systems.
Bookmark this page for verified updates about AIMLF's role in advancing machine learning applications for cardiovascular monitoring, neurodegenerative disorder management, and metabolic health solutions. Visit regularly to maintain current awareness of this innovator's evolving position in digital healthcare markets.
AI/ML Innovations Inc. announces the successful results of its Annual General Meeting held on July 27, 2022. A total of 5,412,712 common shares were voted, representing 15.5% of issued shares, achieving quorum. Key resolutions passed include the election of 4 Directors: Tim Daniels, Nick Watters, Randy Duguay, and Bruce Matichuk, the appointment of Baker Tilly Canada as auditors, and the approval of the Company's Stock Option Plan. For more details, shareholders can refer to the Company's profile on SEDAR.
AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) announces the upcoming launch of Alakin, a comprehensive healthcare management platform developed by its subsidiary Tech2Heal. This SaaS solution, built on FHIR standards, aims to improve patient engagement and optimize workflows in healthcare settings. A pilot study will commence at a 30,000-patient facility in Paris, with full deployment planned for August 2022. Alakin will streamline patient care processes, potentially leading to significant time and cost savings for healthcare providers.
AI/ML Innovations Inc. (CSE:AIML; OTCQB:AIMLF) announced that its subsidiary, Tech2Heal SAS, has been selected as a finalist in the prestigious i-Nov Innovation Contest. This recognition highlights the innovative potential of its Qookka digital therapy for mental health disorders, with less than 10% of entries making the cut. The contest, backed by the Programme d'Investissements d'Avenir in France, offers up to €5M in co-financing for winners. Qookka utilizes advanced AI algorithms and digital biomarkers for enhanced patient support and monitoring.
AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) announced a marketing services agreement with Octagon Media Corp to enhance its digital media presence. The contract, lasting three months, involves monthly payments of US$25,000 and the issuance of 500,000 stock options at CAD$0.20. Additionally, the company granted 800,000 options to management at the same exercise price. Through strategic partnerships and a focus on AI and ML technologies, AI/ML aims to drive growth in the healthcare sector.
AI/ML Innovations Inc. announced a License Agreement with MedWatch Technologies, Inc. to utilize patented health management technology and AI software for diabetes monitoring solutions. MedWatch will pay Health Gauge an annual fee of US$120,000 plus a 2% royalty on gross sales. With diabetes-related medical costs in the US at $327 billion annually, the partnership aims to improve patient outcomes through non-invasive monitoring tools. The agreement spans an initial term of 7 years, with a US$2 million termination fee.
AI/ML Innovations Inc. announced a license agreement with MedWatch Technologies for its patented health management technology, targeting the $327 billion US diabetes market. MedWatch will pay an annual fee of US$120,000 plus a 2% royalty on gross sales, projected to be US$5.00 to US$8.00 per device. The agreement has an initial term of 7 years with automatic renewals and includes a US$2 million early termination fee. This strategic partnership aims to enhance diabetes management through innovative blood glucose monitoring solutions.
AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) has completed a non-brokered private placement, issuing 4 million units at $0.15 per unit, resulting in $600,000 in gross proceeds. Each unit consists of one common share and one share purchase warrant, exercisable at $0.20 for 12 months. The funds will support platform deployment with healthcare clients and general operating expenses. The company incurred $25,337.81 in finder's fees for this offering.
AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) announced that its subsidiary, Tech2Heal SAS, has been selected as a founding participant in the PariSanté Health Tech Campus in Paris, France. This initiative aims to foster collaboration among leading health-tech entities to enhance research and innovation in e-health. Tech2Heal's recognition reflects its leadership in digital mental healthcare. The campus includes prominent players like Inserm and Health Data Hub, providing Tech2Heal access to a rich ecosystem of expertise to strengthen its healthcare solutions.
AI/ML Innovations Inc. announces that its subsidiary, Health Gauge, has received a patent (US Patent No. 11183303) for its wearable health monitoring technology. This technology utilizes machine learning to enhance the accuracy of health metrics such as blood pressure, enabling users to achieve personal health goals. Key features include predictive health analysis and behavioral insights based on data from various bio-signals. The patent solidifies Health Gauge's position in the AI-supported telemedicine field, aimed at improving health monitoring during and beyond the pandemic.
FAQ
What is the current stock price of AI / ML Innovations (AIMLF)?
What is the market cap of AI / ML Innovations (AIMLF)?
